Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Shen YangDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-4983-6787
Eugenio SantelliDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-8739-2750
Carlos G GonzalezDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-4673-4048
Wade T JohnsonDepartment of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-0810-6454
Irene V ChoiDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.
Chuling ZhuangDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0009-0007-0859-9491
Myungja RoDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.
Leigh-Ana M RossittoDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-7744-3630
I-Shing YuLaboratory Animal Center, College of Medicine, National Taiwan University, Taipei 10048, Taiwan.ORCID 0000-0002-2369-5816
Shu-Wha LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10048 Taiwan.ORCID 0000-0001-6748-5581
Yuan ZhanDepartment of Medicine, Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0009-0001-2383-0408
Qinwei ChenDepartment of Medicine, Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0009-0009-1572-0688
Jonathan D YoshiharaDepartment of Medicine, Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0009-0003-8339-346X
Daniel J WallaceDepartment of Medicine, Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-2502-1372
Caroline A JefferiesDepartment of Medicine, Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-8879-6722
Michifumi YamashitaDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0001-6221-8900
David J GonzalezDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-1423-5970
Richard I AinsworthDepartment of Medicine, Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Nisarg J ShahDepartment of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-1727-5732
Stephanie M StanfordDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.
Nunzio BottiniDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9025-7501
Funding
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Role of PTPN2 in rheumatoid arthritisR01AI148073 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOTTINI, NUNZIO · 2019 to 2023
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is encoded by a gene strongly associated with lupus and other autoimmune diseases. PTPN22 regulates T cell receptor (TCR) signaling through dephosphorylation of the kinases lymphocyte-specific protein tyrosine kinase (LCK) and zeta-chain-associated protein kinase 70 (ZAP70). The regulation of PTPN22 remains poorly understood. Here, we identify PTPN22 Ser
Indexed as
AutoimmunityFeedback, PhysiologicalLeukocyte Common AntigensProtein Tyrosine Phosphatase, Non-Receptor Type 22Receptors, Antigen, T-CellSignal TransductionAnimalsHumansLymphocyte Specific Protein Tyrosine Kinase p56(lck)MicePhosphorylationT-LymphocytesZAP-70 Protein-Tyrosine KinaseLeukocyte Common AntigensLymphocyte Specific Protein Tyrosine Kinase p56(lck)Protein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, humanPtpn22 protein, mousePTPRC protein, humanPtprc protein, mouseReceptors, Antigen, T-CellZAP-70 Protein-Tyrosine Kinase
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
PTPN22-CD45 dual phosphatase retrograde feedback enhances TCR signaling and autoimmunity. · full record | Socratic